Targeting Cell Signaling Pathways in Lung Cancer by Bioactive Phytocompounds

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Lung cancer is a leading cause of cancer-related mortality globally, characterized by high incidence and heterogeneous malignancy.
• Aberrant signaling pathways, including those regulating apoptosis, growth inhibition, and promotion, are critical in lung cancer pathogenesis.
• Existing treatments for lung cancer exhibit variable efficacy, necessitating the exploration of novel therapeutic strategies.

Purpose of the Study:

• To review the key signaling pathways implicated in lung cancer pathophysiology.
• To discuss current lung cancer treatments and potential therapeutic targets.
• To evaluate the anticancer potential and mechanistic actions of phytochemicals in lung cancer.

Main Methods:

• Literature review of preclinical and clinical studies on lung cancer signaling pathways.
• Analysis of signaling molecules involved in apoptosis, growth inhibition, and promotion.
• Examination of plant-based compounds (phytochemicals) as anticancer agents.

Main Results:

• Several signaling cascades, such as those involving BCL2, TP53, and EGFR/PI3K, are crucial in lung cancer development.
• Phytochemicals demonstrate significant anticancer activity through diverse mechanisms.
• Preclinical and clinical data support the therapeutic potential of phytochemicals against lung cancer.

Conclusions:

• Targeting aberrant signaling pathways is a key strategy in lung cancer therapy.
• Phytochemicals represent a promising class of natural compounds for lung cancer chemoprevention and chemotherapy.
• Further research into phytochemical mechanisms can lead to novel lung cancer drug development.